{"altmetric_id":18770984,"citation":{"altmetric_jid":"clinicaltrialsgov","authors":["Bristol-Myers Squibb"],"first_seen_on":"2017-04-12T16:12:54+00:00","issns":[],"journal":"ClinicalTrials.gov","last_mentioned_on":1493006400,"links":["https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02985957","https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02985957?term=ipilimumab+AND+Bristol+AND+prostate&rank=3"],"nct_id":"NCT02985957","pubdate":"2016-11-22T00:00:00+00:00","publisher":"ClinicalTrials.gov","title":"A Study to Evaluate Preliminary Safety and Efficacy of Nivolumab Plus Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)","type":"clinical_trial_study_record"},"altmetric_score":{"score":15,"score_history":{"1y":15,"6m":15,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":15},"context_for_score":{"all":{"total_number_of_other_articles":8093859,"mean":6.8854427063012,"rank":544091,"this_scored_higher_than_pct":93,"this_scored_higher_than":7544055,"rank_type":"exact","sample_size":8093859,"percentile":93},"similar_age_3m":{"total_number_of_other_articles":239707,"mean":12.93780543666,"rank":27911,"this_scored_higher_than_pct":88,"this_scored_higher_than":211698,"rank_type":"exact","sample_size":239707,"percentile":88},"this_journal":{"total_number_of_other_articles":22982,"mean":10.489420564814,"rank":1831,"this_scored_higher_than_pct":91,"this_scored_higher_than":21109,"rank_type":"exact","sample_size":22982,"percentile":91},"similar_age_this_journal_3m":{"total_number_of_other_articles":675,"mean":8.0158278931751,"rank":34,"this_scored_higher_than_pct":94,"this_scored_higher_than":641,"rank_type":"exact","sample_size":675,"percentile":94}}},"demographics":[],"counts":{"total":{"posts_count":3},"news":{"unique_users_count":2,"unique_users":["oncology_nurse_advisor","mit_technology_review"],"posts_count":3}},"posts":{"news":[{"title":"Prostate Cancer Response to Immunotherapy Improved With Combination Therapy","url":"http:\/\/www.oncologynurseadvisor.com\/combination-treatment-boosts-prostate-cancer-responsiveness-to-immunotherapy\/article\/649995\/","license":"public","citation_ids":[18770984,18169686,18169686],"posted_on":"2017-04-12T15:00:00+00:00","summary":"April 12, 2017 Researchers assessed additional pathways inhibiting the immune system in the tumor microenvironment by evaluating untreated and ipilimumab-treated tumor samples.","author":{"name":"Oncology Nurse Advisor ","url":"http:\/\/www.oncologynurseadvisor.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/276\/normal\/Screen_Shot_2014-11-20_at_11.19.42.png?1416482413"}},{"title":"Prostate Cancer Response to Immunotherapy Improved With Combination Therapy","url":"http:\/\/ct.moreover.com\/?a=30213636044&p=1pl&v=1&x=90rYMAQh-4iE5LxU5zzXGw","license":"public","citation_ids":[18770984,18169686,18169686],"posted_on":"2017-04-12T15:00:00+00:00","summary":"April 12, 2017 Researchers assessed additional pathways inhibiting the immune system in the tumor microenvironment by evaluating untreated and ipilimumab-treated tumor samples.","author":{"name":"Oncology Nurse Advisor ","url":"http:\/\/www.oncologynurseadvisor.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/276\/normal\/Screen_Shot_2014-11-20_at_11.19.42.png?1416482413"}},{"title":"The unfinished business of immunotherapy","url":"http:\/\/ct.moreover.com\/?a=30334432464&p=1pl&v=1&x=UTSABB67OpUNnFHHd5Iv8w","license":"public","citation_ids":[18770984],"posted_on":"2017-04-24T04:00:00+00:00","summary":"On the day I arrive at MD Anderson Cancer Center in Houston to meet James Allison and his longtime collaborator Padmanee Sharma, they are nowhere to be found.","author":{"name":"MIT Technology Review","url":"http:\/\/www.technologyreview.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/045\/normal\/mit_technology_review.png?1369846935"}}]}}